PAQ Therapeutics
PrivateLast Round
Series B
Extension
Jan 22, 2026
Total Funding Raised
$153M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
PAQ Therapeutics is a biotechnology company developing best- and first-in-class KRAS degraders for lethal cancers lacking effective treatment options.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PAQ Therapeutics Comparables
Compare PAQ Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Casma Therapeutics | 91% | |
| Automera | 89% | |
| Samsara Therapeutics | 88% |
PAQ Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jan 22, 2026 | ||||
| Series B | May 7, 2025 | ||||
| Series A | Jul 15, 2021 | ||||
| Seed | Nov 8, 2020 | ||||
| Seed | Jun 1, 2020 |
PAQ Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Matrix | Seed, Series A |
| BioTrack Capital | Series B Extension, Series B |
| Nest.Bio | Seed, Series A |
| MSA Capital | Series A |
| Bayland Capital | Series B Extension |
| MPC | Seed, Series A |
| Huagai Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2026
Monthly visitors grew 398% MoM, from 386 to 1.9K.
- Jan 22, 2026
$38M round with participation from Merck and J&J.
PAQ Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about PAQ Therapeutics's valuation, stock price, and market status.
Is PAQ Therapeutics a public or private company?
PAQ Therapeutics is a private company.
What is the current stock price of PAQ Therapeutics?
PAQ Therapeutics is a private company, so its shares have no public market price. Caplight tracks PAQ Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PAQ Therapeutics worth (valuation)?
Valuation information for PAQ Therapeutics is not publicly available.
Can I buy PAQ Therapeutics stock?
PAQ Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PAQ Therapeutics's last funding round?
PAQ Therapeutics's most recent funding round was Series B Extension on January 22, 2026.
Who are the main investors in PAQ Therapeutics?
Key investors in PAQ Therapeutics include Sherpa Healthcare Partners.
Will PAQ Therapeutics IPO soon?
No public IPO plans have been announced for PAQ Therapeutics.
How can I track PAQ Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in PAQ Therapeutics's shares on secondary markets.